Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Noevir Holdings Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 14.18%.
Noevir Holdings Co (TSE:4928) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Noevir Holdings Co ROCE % Related Terms
Noevir Holdings Co ROCE % Historical Data
* Premium members only.
The historical data trend for Noevir Holdings Co's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noevir Holdings Co (TSE:4928) has a ROCE % of 14.18% as of Dec. 2025.
Is Noevir Holdings Co's ROCE % too high?
Noevir Holdings Co's current ROCE % is 14.18%. The Consumer Packaged Goods industry median ROCE % is 8.81. Noevir Holdings Co's value of 14.18% is 61% above this industry median. Overall, Noevir Holdings Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Noevir Holdings Co's ROCE % compare to PG and CL?
Noevir Holdings Co's ROCE % of 14.18% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROCE % is 8.81. Noevir Holdings Co's value of 14.18% is 61% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Consumer Packaged Goods company?
The median ROCE % among Consumer Packaged Goods companies is 8.81, based on 1,944 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noevir Holdings Co's current ROCE % of 14.18% is 61% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median ROCE % is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noevir Holdings Co's current ROCE % is 14.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noevir Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Noevir Holdings Co (TSE:4928) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,265.32, compared to a current price of 円4,585.00 — trading 12.9% below its estimated fair value. The current ROCE % is 14.18% and 61% above the Consumer Packaged Goods industry median of 8.81. Noevir Holdings Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Noevir Holdings Co (TSE:4928), the current ROCE % is 14.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noevir Holdings Co (TSE:4928) Overvalued in 2026?
Based on GuruFocus' analysis, Noevir Holdings Co stock appears to be undervalued.
The current stock price of 円4,585.00 is trading 12.9% below its estimated GF Value™ of 円5,265.32.
GuruFocus considers Noevir Holdings Co to be Modestly Undervalued.
Key valuation signals for TSE:4928:
ROCE %: 14.18%
GF Value™: 円5,265.32 vs. price of 円4,585.00 (12.9% below fair value)
Industry Position: 61% above the Consumer Packaged Goods median
No single metric tells the full story. See the TSE:4928 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noevir Holdings Co Ltd is a Japan-based company that is principally engaged in two businesses: cosmetics and pharmaceuticals and health food. The cosmetics business produces and offers skincare and makeup products under a number of brands, like Noevir, NOV, and Sana. The pharmaceuticals and health food business develops, produces, and sells a broad range-of-products, including Nanten Nodo Ame cough drops, functional drinks, and other over-the-counter pharmaceuticals, such as cold remedies and eye drops, and health food products as well. These two businesses jointly contribute the majority of the company's revenue. The company also operates apparel and aircraft sales and leasing. The company has a presence in many countries across the world and focuses on developing Asian markets.
79GF Score
Get the complete analysis for TSE:4928
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4928 has been successfully added to your 
